Duvelisib free base · Synonyms: IPI-145 | INK 1197

Duvelisib is a novel and selective PI3K δ/γ inhibitor.

For research use only. Not for human or veterinary use.

Target PI3K

Research area Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

Duvelisib structure

CAS No.: 1201438-56-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 550.00	BP-02331-250mg	In stock	Get quote
500 mg	USD 850.00	BP-02331-500mg	In stock	Get quote
1 g	USD 1,300.00	BP-02331-1g	In stock	Get quote
2 g	USD 2,100.00	BP-02331-2g	In stock	Get quote
3 g	USD 2,800.00	BP-02331-3g	In stock	Get quote
5 g	Inquire	BP-02331-5g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays.

Biological activity

Duvelisib (IPI-145) is a novel and selective PI3K δ/γ inhibitor with IC50 of 23 pM and 243 pM, respectively. IPI-145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Duvelisib (IPI-145) suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM. IPI-145 was well tolerated and clinically active in a broad range of malignancies, including iNHL. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model.

Identifiers

SMILES: C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
InChIKey: SJVQHLPISAIATJ-ZDUSSCGKSA-N

Specifications

MW (average): 416.8630
Formula: C₂₂H₁₇ClN₆O
CAS No.: 1201438-56-3
Physical state: Solid
Color: Off-white to gray
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795.

[2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42.

Same target

Search PI3K

Same research area

Search Cancer